- The FDA has lifted the clinical hold on Celyad Oncology SA’s (NASDAQ:CYAD) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the company made changes to the eligibility criteria for the trial.
- “We remain confident in the potential development of not only the candidate itself, but the continued development with our proprietary TIM technology. CYAD-101 is currently our only clinical candidate co-expressing NKG2D and TIM, and we hope to continue to showcase our expertise with our non-gene edited technologies and explore additional opportunities to utilize NKG2D in allogeneic CAR T,” said Charles Morris, Chief Medical Officer of Celyad Oncology.
- In February, the company voluntarily paused the CYAD-101-002 trial to investigate reports of two fatalities in the study.
- The FDA subsequently put the trial on clinical hold in March.
- The CYAD-101-002 Phase 1b trial evaluates CYAD-101 with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in refractory metastatic colorectal cancer with microsatellite stable (MSS) / mismatch-repair proficient disease.
- Price Action: CYAD shares are up 28.1% at $2.23 during the premarket session on the last check Monday.
Pfizer: Q2 Earnings Insights
Pfizer (NYSE:PFE) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:45 AM.
Here's what investors need to know about the announcement.
Earnings
Pfizer beat estimated earnings by 13.33%, reporting an EPS of $2.04 versus an estimate of $1.8.
